Stephen Thomas, Ph.D.
Board Member
Stephen, previously CEO and co-founder of Tenet Medicines, Inc., brings broad experience in drug discovery and development, business development, and capital raises. Prior to Tenet, Mr. Thomas served as CSO of ValenzaBio, Inc., a clinical-stage biotechnology company, up until its acquisition by ACELYRIN, INC. At ValenzaBio, Mr. Thomas led the successful development of three antibody pipeline programs in I&I from preclinical to clinical proof-of-concept, including the anti-IGF-1R monoclonal antibody lonigutamab, and served a pivotal role in overall corporate strategy and fundraisings. Prior to ValenzaBio, Mr. Thomas was CSO and co-founder of Ichorion Therapeutics, Inc., where he built and advanced a pipeline of therapies for rare pediatric diseases up until its acquisition by Cerecor, Inc. Mr. Thomas holds a Ph.D. in organic synthesis and chemical biology from Columbia University, where he was a Bristol-Myers Squibb Fellow and NSF Predoctoral Fellow, and was previously an Amgen Scholar.